Women's knee injury risk: new study probes hormone link
NCT ID NCT05177549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how hormones and birth control pills affect knee ligament looseness in healthy women. Researchers measured knee laxity in 45 women at two points in their menstrual cycle, comparing those on hormonal contraceptives to those not. The goal was to better understand why women have a higher risk of ACL knee injuries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
45 people
The number who actually took part.
- Started
-
Jun 2022
- Finished
-
Aug 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Woman between 18 and 40 years old * No history of surgery of the 2 lower limbs * No change in contraceptive method in the last 6 months * Signature of the informed consent * Affiliation to the social security system * To be at Day 14 of her menstrual cycle (+/-1 day) (the first day of the cycle (Day1) being considered as the first day of the menstrual period), except for those on micro-progestative contraception not regulated By inclusion group: \- For women without hormonal contraception: No method of contraception Or a copper intrauterine device Regular cycles of 26 to 33 days \- For women on estrogen-progestin contraception: Correct use of the estrogen-progestin pill according to the MA Or wearing a vaginal ring according to the MA protocol Or wearing a contraceptive skin patch according to the MA protocol Regular cycles of 26 to 33 days \- For women on micro-progestin contraception : Continuous use of the micro-progestogen pill Or wearing a subcutaneous hormonal implant, Exception: women on micro-progestin contraception who are not regulated: * They may have an irregular cycle or no cycle to be included * They can be included on any day if they have no cycle Exclusion Criteria: * Pregnancy or breastfeeding in progress * Hormonal intrauterine device or injectable contraception * Menopause (defined as no menstruation for one year) * Surgery: tubal ligation, oophorectomy, adnexectomy, hysterectomy * History of microcrystalline or infectious pathology localized to the knee * History of systemic or localized inflammatory joint disease of the knee * History of fracture, severe sprain or dislocation of the knee joint * History of osteoarticular or congenital diseases that may lead to laxity (Marfan syndrome, trisomy 21, Ehlers-Danlos syndrome...) * Sign of hyperlaxity evaluated by a Beighton score higher than 4 (see appendix) * BMI \> 25 * Daily alcohol consumption above the thresholds recommended by Public Health in France (more than 2 glasses per day) * Woman unable to understand the protocol * Intense or unusual physical exercise during the last 72 hours (e.g.: marathon, triathlon, competitive cycling race...) * Woman under guardianship, curatorship or deprived of liberty
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ligament; laxity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nice
Nice, 06300, France